Clinical features and treatment of drug fever caused by anti-tuberculosis drugs

被引:9
|
作者
Fang, Yong [1 ]
Xiao, Heping [1 ]
Tang, Shenjie [1 ]
Liang, Li [1 ]
Sha, Wei [1 ]
Fang, Yuanyuan [1 ]
机构
[1] Tongji Univ, Sch Med, Shanghai Key Lab TB, TB Ctr Diag & Treatment,Shanghai Pulm Hosp, Shanghai 200433, Peoples R China
来源
CLINICAL RESPIRATORY JOURNAL | 2016年 / 10卷 / 04期
关键词
adverse reaction; anti-tuberculosis drugs; drug fever; treatment;
D O I
10.1111/crj.12242
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background and AimsTuberculosis is a major global health problem. However, anti-tuberculosis drug treatment has many adverse effects, such as drug-caused fever. The aim of this study was to investigate the clinical features and treatments of anti-tuberculosis drugs-induced fever. MethodsA total of 78 inpatients and outpatients with pulmonary tuberculosis accompanied by drug fever during the anti-tuberculosis treatment were analysed retrospectively from April 2006 to March 2013. ResultsAmong the anti-tuberculosis drugs that caused the drug fever, rifampicin was the most common one, followed by para-aminosalicylic and pyrazinamide. The symptoms occurred within 2 months after treatment, mainly in the 1-3 weeks, and the main symptom was high fever with body temperature above 39 degrees C. The accompanying symptoms include rash, chills, headache, stuffy nose, runny nose, nausea, vomiting and joint pain. Routine blood examination found that eosinophilia increased in 15 cases and decreased in another 15. Among 63 patients who underwent liver function tests, there were 10 cases of abnormal function and 4 cases of liver damage. When the drug fever was suspected, the measure of withdrawal was taken first. All the suspected drugs were withdrawn in 59 cases, while gradual withdrawal was conducted in 19 cases. Patients with complications were first treated in accordance with the principles of complications treatment and then were gradually given some drugs after recovery. The patients without complications were gradually given some drugs after the body temperature was back to normal. ConclusionDrug fever is an allergic reaction, the resolution of which depends on whether it was accompanied by liver damage and/or rash or not.
引用
收藏
页码:449 / 454
页数:6
相关论文
共 50 条
  • [31] Prospects for new anti-tuberculosis drugs
    Duncan, K
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1997, 49 : 21 - 23
  • [32] Adverse Reaction to Anti-tuberculosis Drugs
    Chantaphakul, H.
    Cheungpasitporn, W.
    Ruxrungtham, K.
    Klaewsongkram, J.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (02) : AB154 - AB154
  • [33] Manifestations of hypersensitivity to anti-tuberculosis drugs
    Benbetka, Yacine
    Souilah, Souad
    Fissah, Aziza
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [34] Pharmacokinetics of Anti-tuberculosis Drugs in Children
    Geetha Ramachandran
    A. K. Hemanth Kumar
    Soumya Swaminathan
    The Indian Journal of Pediatrics, 2011, 78 : 435 - 442
  • [35] DIAZEPAM INTERACTION WITH ANTI-TUBERCULOSIS DRUGS
    OCHS, HR
    GREENBLATT, DJ
    ROBERTS, GM
    DENGLER, HJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 29 (05) : 671 - 678
  • [36] Pharmacokinetics of Anti-tuberculosis Drugs in Children
    Ramachandran, Geetha
    Kumar, A. K. Hemanth
    Swaminathan, Soumya
    INDIAN JOURNAL OF PEDIATRICS, 2011, 78 (04): : 435 - 442
  • [37] INTERACTION OF DIAZEPAM WITH ANTI-TUBERCULOSIS DRUGS
    OCHS, HR
    GREENBLATT, DJ
    ROBERTS, GM
    DENGLER, HJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 29 (02) : 270 - 270
  • [38] Drug-drug interaction studies on first-line anti-tuberculosis drugs
    Bhutani, H
    Singh, S
    Jindal, KC
    PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2005, 10 (04) : 517 - 524
  • [39] Anti-tuberculosis treatment strategies and drug development: challenges and priorities
    Véronique A. Dartois
    Eric J. Rubin
    Nature Reviews Microbiology, 2022, 20 : 685 - 701
  • [40] Anti-tuberculosis treatment strategies and drug development: challenges and priorities
    Dartois, Veronique A.
    Rubin, Eric J.
    NATURE REVIEWS MICROBIOLOGY, 2022, 20 (11) : 685 - 701